A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif 44 Mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group.

Trial Profile

A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif 44 Mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors EMD Serono
  • Most Recent Events

    • 03 May 2014 Results for the effect on brain volume presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 03 May 2014 Results for the correlation between immunological biomarkers and changes in normal-appearing brain tissue presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 03 Apr 2012 Actual patient number (38) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top